



ATTORNEYS AT LAW

PATENT AND TRADEMARK CAUSES

SUITE 300

624 NINTH STREET, N.W.

WASHINGTON, D. C. 20001-5303

TELEPHONE (202)-628-5197

June 28, 2001

TELECOPIER FACSIMILE (202) 737-3528 (202) 393-1012 E MAIL mail@browdyneimark.com PATENT AGENT

ALLEN C. YUN, PHD *ADMITTED IN FLONLY PRACTICE SUPERVISED BY PRINCIPALS OF THE FIRM

Hon. Assistant Commissioner for Patents Box Patent Appln Washington, D.C. 20231

Re

or coursel.

IVER. P. COOPER JAY M. FINKELSTEIN

New C.I.P. Patent Application in U.S.

Applicant: Michal EISENBACH-SCHWARTZ et al.

ACTIVATED T-CELLS, NERVOUS SYSTEM-SPECIFIC ANTIGENS...

Atty's Docket: EIS-SCHWARTZ 2A

Sir:

Attached herewith is the above-identified continuation-in-part application for Letters Patent including:

Application Data Sheet

Specification (103 pages), claims (8 pages), abstract (1 page) and sequence listing (57 pages)

30 Sheets Drawings (Figures 1-25)

[X] FORMAL []

Sequence Listing with disk and Statements in accordance with 37 C.F.R. §37 C.F.R. §1.821(f) and 1.821(4). Preliminary Communication

The inventors of this application are:

Michal EISENBACH-SCHWARTZ, of 5 Rupin Street, Rehovot 76353, Israel;

Irun R. COHEN, of 11 Hankin Street, Rehovot 76353, Israel;

Pierre BESERMAN, of Moshav Sitriya 76834, Israel;

Alon MOSONEGO, of Ben-Yosef, Kfar Hanoar Ben-Shemen 73112, Israel; and

Gila MOALEM, of 27 Bosel Street, Rehovot 76405, Israel.

Information Disclosure Statement with SB/08A and ____ references

Return Receipt Postcard (in duplicate) [X]

The following statements are applicable:

- Applicant hereby requests that this application not be published pursuant to 35 U.S.C. §122(a). It is certified on behalf of applicant that the invention disclosed in the application has not been and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing.
- Applicant claims small entity status. See 37 C.F.R. §1.27.
- The benefit under 35 USC §119 is claimed of the filing date of: Application No. 124500 in Israel on 19 May 1998. A certified copy of said priority document was filed [X] in parent PCT application no. PCT/US98/14715.

The present application claims the benefit of U.S. Provisional Appln. No. 60/, filed [X] The present application is a Continuation-in-Part of prior Application No. 09/314,161, filed May 19, 1999, which is a CIP of 09/218,277, filed December 22, 1998, which is a CIP of International Application No. PCT/US98/14715, filed July 21, 1998. Although this application is stated to be a CIP, applicant does not concede that any matter is presented in this application which is not present in the parent.
[] Amend the specification by inserting before the first line the sentence: []This is a continuation / division / continuation-in-part of copending parent application No filed []The present application claims the benefit of U.S. Provisional Appln. No. 60/, filed
-The present application is the national stage under 35 U.S.C. §371 of international application which designated the United States, which international application was published
[X] The application is (or will be) assigned to: YEDA RESEARCH AND DEVELOPMENT CO. LTD., whose address is Weizmann Institute of Science, P.O. Box 95, Rehovot, Israel 76 100.

- Certain documents were previously cited or submitted to the Patent and Trademark Office in the following prior application 09/314,161, which is relied upon under 35 USC §120. Applicants identify [X] these documents by attaching hereto form PTO-1449s listing these documents, and request that they be considered and made of record in accordance with 37 CFR §1.98(d). Per Section 1.98(d), copies of these documents need not be filed in this application.
- Incorporation By Reference. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied herewith, is considered as being part of the disclosure of the accompanying [] application and is hereby incorporated by reference therein.
- In accordance with 37 CFR 1.53(a) and (b), it is respectfully requested that a serial number and filing date be assigned to this application as of the date of receipt of the present papers. In accordance with [X] the present procedures of the U.S. Patent and Trademark Office, an executed Declaration and the filing fee for the present application will be filed in due course.
- No authorization is given for charging the filing fee at the present time. However, at such time that the declaration is filed, but not before, you are authorized to charge whatever excess fees [X] are necessary (including the filing fee and any extension of time fees then due) to Deposit Account 02-4035, if any such fees due are not fully covered by check filed at that time.
- The attorneys of record for this application and the address will be those of **Customer No. 001444**; i.e., Sheridan Neimark, Reg. No. 20,520; Roger L. Browdy, Reg. No. 25,618; Anne M. Kornbau, Reg. [X]No. 25,884; Norman J. Latker, Reg. 19,963; Iver P. Cooper, Reg. No. 28,005; Jay M. Finkelstein, Reg. No. 21,082; and *Allen C. Yun, Reg. No. 37,971 (*Patent Agent). Please send all correspondence with respect to this case to:

BROWDY AND NEIMARK, P.L.L.C. 624 Ninth Street, N.W. Washington, D.C. 20001

Please direct all telephone calls to Browdy and Neimark at (202) 628-5197.

The Commissioner is hereby authorized to credit any overpayment of fees accompanying this paper to [X]Deposit Account No. 02-4035.

Respectfully submitted,

BROWDY ND NEIMARK, P.L.L.C

Roger L. Browdy

Registration No. 25,618

RLB:edg

F:\,Y\YEDA\eis-schwartz2a\Pto\newCIP53transmittal2.doc